2617 BISSONNET ST, HOUSTON, TX
Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
Termination of Engagement Letter with Cantor Fitzgerald & Co.
Other Events
Changes in Board, Management or Compensation
News
News, Articles of Incorporation
Material disclosure
FY 2025
Q3
Q2
Q1
Amended Annual Report
FY 2024
Amended Registration Statement for Securities Offered under a Shelf Registration
S-1
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Prospectus filed pursuant to Rule 424(b)(8)